GlassScriptPhysician profile
Oana C Danciu
NPI 1043409394
$53,259.58
in general payments reported to CMS, 2019-2025
21 companies · $39K in 2025
The $39K reported for 2025 was more than what 95% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,191 · 2020: $18.10 · 2021: $115 · 2022: $5,860 · 2023: $2,568 · 2024: $4,856 · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $44K · Food and Beverage: $1,743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $44,332.61 |
| Food and Beverage | $1,743.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $28,626.86 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $8,568.51 | 2023-2025 | Lynparza, Enhertu |
| Gilead Sciences, INC. | $5,730.65 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $3,943.01 | 2023-2024 | Kisqali |
| Bayer Healthcare Pharmaceuticals INC. | $2,271.79 | 2025 | |
| Pfizer INC. | $2,099.61 | 2019-2025 | |
| Puma Biotechnology, INC. | $1,195.59 | 2019-2024 | |
| Stemline Therapeutics INC. | $282.43 | 2022-2025 | Orserdu |
| Beigene USA, INC. | $166.60 | 2024-2025 | Brukinsa, Tevimbra |
| E.R. Squibb & Sons, L.L.C. | $129.06 | 2023 | Onureg |
| Lilly USA, LLC | $103.13 | 2021 | |
| Daiichi Sankyo INC. | $28.89 | 2024 | Enhertu |
| Sanofi-Aventis U.S. LLC | $28.68 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.55 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.10 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $21.02 | 2022 | |
| Exelixis INC. | $18.10 | 2020 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oana Danciu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.